Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer

Yoneda,Tomoko; Kuboyama,Ayumi; Kato,Kiyoko; Ohgami,Tatsuhiro; Okamoto,Kanako; Saito,Toshiaki; Wake,Norio

doi:10.3892/or.2013.2433

Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer

Authors:
- Tomoko Yoneda
- Ayumi Kuboyama
- Kiyoko Kato
- Tatsuhiro Ohgami
- Kanako Okamoto
- Toshiaki Saito
- Norio Wake
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, School of Medicine, Kyushu University, Fukuoka 812‑8582, Japan, Gynecology Service, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
Published online on: April 29, 2013 https://doi.org/10.3892/or.2013.2433
Pages: 25-34
Copyright: © Yoneda et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The incidence of endometrial cancer, a common gynecological malignancy, is increasing in Japan. We have previously shown that the ER/MDM2/p53/p21 pathway plays an important role in endometrial carcinogenesis. In the present study, we investigated the effects of germline single nucleotide polymorphisms in murine double minute 2 (MDM2) SNP309, TP53 Arg72Pro, ESR1 PvuII and XbaI, and p21 codon 31 on endometrial cancer risk. We evaluated these polymorphisms in DNA samples from 125 endometrial cancer cases and 200 controls using polymerase chain reaction-based restriction fragment length polymorphism. The association of each genetic polymorphism with endometrial cancer was examined by the odds ratio and 95% confidence interval, which were obtained using logistic regression analysis. The SNP309 GG genotype non-significantly increased the risk of endometrial cancer. The 95% confidence interval for the GG genotype vs. the TT genotype of MDM2 SNP309 was 1.76 (0.93-3.30). Endometrial cancer was not associated with tested SNP genotypes for TP53, ESR1 and p21. The combination of SNP309 GG + TG and TP53 codon 72 Arg/Arg significantly increased endometrial cancer risk. The adjusted OR was 2.53 (95% confidence interval, 1.03-6.21) and P for the interaction was 0.04. This result was supported by in vitro data showing that endometrial cancer cell lines with the SNP309 G allele failed to show growth inhibition by treatment with RITA, which reduces p53-MDM2 binding. The presence of the SNP309 G allele and TP53 codon 72 Arg/Arg genotype is associated with an increased risk of endometrial cancer in Japanese women.

View Figures

View References

1	Bansal N, Yendluri V and Wenham RM: The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control. 16:8–13. 2009.PubMed/NCBI
2	Prat J, Gallardo A, Cuatrecasas M and Catasus L: Endometrial carcinoma: pathology and genetics. Pathology. 39:72–87. 2007. View Article : Google Scholar
3	Deb SP: Cell cycle regulatory functions of the human oncoprotein MDM2. Mol Cancer Res. 1:1009–1016. 2003.PubMed/NCBI
4	Haupt Y, Maya R, Kazaz A and Oren M: Mdm2 promotes the rapid degradation of p53. Nature. 387:296–299. 1997. View Article : Google Scholar : PubMed/NCBI
5	Honda R, Tanaka H and Yasuda H: Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420:25–27. 1997. View Article : Google Scholar : PubMed/NCBI
6	Kubbutat MH, Jones SN and Vousden KH: Regulation of p53 stability by Mdm2. Nature. 387:299–303. 1997. View Article : Google Scholar : PubMed/NCBI
7	Levav-Cohen Y, Haupt S and Haupt Y: Mdm2 in growth signaling and cancer. Growth Factors. 23:183–192. 2005. View Article : Google Scholar : PubMed/NCBI
8	Gudas JM, Nguyen H, Klein RC, Katayose D, Seth P and Cowan KH: Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells. Clin Cancer Res. 1:71–80. 1995.PubMed/NCBI
9	Sheikh MS, Shao ZM, Hussain A and Fontana JA: The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res. 53:3226–3228. 1993.PubMed/NCBI
10	Ries S, Biederer C, Woods D, et al: Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell. 103:321–330. 2000. View Article : Google Scholar : PubMed/NCBI
11	Kato K, Ueoka Y, Hachiya T, Nishida J and Wake N: Contribution of enhanced transcriptional activation by ER to [12Val] K-Ras mediated NIH3T3 cell transformation. Oncogene. 15:3037–3046. 1997.
12	Kato K, Horiuchi S, Takahashi A, et al: Contribution of estrogen receptor α to oncogenic K-Ras-mediated NIH3T3 cell transformation and its implication for escape from senescence by modulating the p53 pathway. J Biol Chem. 277:11217–11224. 2002.
13	Suga S, Kato K, Ohgami T, et al: An inhibitory effect on cell proliferation by blockage of the MAPK/estrogen receptor/MDM2 signal pathway in gynecologic cancer. Gynecol Oncol. 105:341–350. 2007. View Article : Google Scholar : PubMed/NCBI
14	Bond GL, Hu W, Bond EE, et al: A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 119:591–602. 2004. View Article : Google Scholar
15	Bond GL, Hirshfield KM, Kirchhoff T, et al: MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res. 66:5104–5110. 2006. View Article : Google Scholar : PubMed/NCBI
16	Campbell IG, Eccles DM and Choong DY: No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett. 240:195–197. 2006. View Article : Google Scholar : PubMed/NCBI
17	Petenkaya A, Bozkurt B, Akilli-Ozturk O, Kaya HS, Gur-Dedeoglu B and Yulug IG: Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk. Anticancer Res. 26:4975–4977. 2006.PubMed/NCBI
18	Krekac D, Brozkova K, Knoflickova D, et al: MDM2SNP309 does not associate with elevated MDM2 protein expression or breast cancer risk. Oncology. 74:84–87. 2008. View Article : Google Scholar : PubMed/NCBI
19	Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature. 408:307–310. 2000. View Article : Google Scholar : PubMed/NCBI
20	el-Deiry WS, Tokino T, Velculescu VE, et al: WAF1, a potential mediator of p53 tumor suppression. Cell. 75:817–825. 1993. View Article : Google Scholar : PubMed/NCBI
21	Roh J, Kim M, Kim J, et al: Polymorphisms in codon 31 of p21 and cervical cancer susceptibility in Korean women. Cancer Lett. 165:59–62. 2001. View Article : Google Scholar : PubMed/NCBI
22	Roh JW, Kim JW, Park NH, et al: p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer. Gynecol Oncol. 93:499–505. 2004. View Article : Google Scholar : PubMed/NCBI
23	Hachiya T, Kuriaki Y, Ueoka Y, Nishida J, Kato K and Wake N: WAF1 genotype and endometrial cancer susceptibility. Gynecol Oncol. 72:187–192. 1999. View Article : Google Scholar : PubMed/NCBI
24	Walsh CS, Miller CW, Karlan BY and Koeffler HP: Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Gynecol Oncol. 104:660–664. 2007. View Article : Google Scholar : PubMed/NCBI
25	Terry K, McGrath M, Lee IM, Buring J and De Vivo I: MDM2 SNP309 is associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev. 17:983–986. 2008. View Article : Google Scholar : PubMed/NCBI
26	Ueda M, Yamamoto M, Nunobiki O, et al: Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer. Hum Cell. 22:49–54. 2009. View Article : Google Scholar : PubMed/NCBI
27	Ueda M, Terai Y, Kanda K, et al: Germline polymorphism of p53 codon 72 in gynecological cancer. Gynecol Oncol. 100:173–178. 2006. View Article : Google Scholar : PubMed/NCBI
28	Yaich L, Dupont WD, Cavener DR and Parl FF: Analysis of the Pvu II restriction fragment-length polymorphism and exon structure of the estrogen receptor gene in breast cancer and peripheral blood. Cancer Res. 52:77–83. 1992.
29	Mizunuma H, Hosoi T, Okano H, et al: Estrogen receptor gene polymorphism and bone mineral density at the lumbar spine of pre- and postmenopausal women. Bone. 21:379–383. 1997. View Article : Google Scholar : PubMed/NCBI
30	Sun Y, Hildesheim A, Li H, et al: No point mutation but a codon 31ser→arg polymorphism of the WAF-1/CIP-1/p21 tumor suppressor gene in nasopharyngeal carcinoma (NPC): the polymorphism distinguishes Caucasians from Chinese. Cancer Epidemiol Biomarkers Prev. 4:261–267. 1995.PubMed/NCBI
31	Shih CM, Lin PT, Wang HC, Huang WC and Wang YC: Lack of evidence of association of p21WAF1/CIP1 polymorphism with lung cancer susceptibility and prognosis in Taiwan. Jpn J Cancer Res. 91:9–15. 2000. View Article : Google Scholar : PubMed/NCBI
32	Issaeva N, Bozko P, Enge M, et al: Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med. 10:1321–1328. 2004. View Article : Google Scholar : PubMed/NCBI
33	Ashton KA, Proietto A, Otton G, et al: Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer. Gynecol Oncol. 113:109–114. 2009. View Article : Google Scholar : PubMed/NCBI
34	Niwa Y, Hirose K, Matsuo K, et al: Association of p73 G4C14-to-A4T14 polymorphism at exon 2 and p53 Arg72Pro polymorphism with the risk of endometrial cancer in Japanese subjects. Cancer Lett. 219:183–190. 2005. View Article : Google Scholar : PubMed/NCBI
35	Nunobiki O, Ueda M, Yamamoto M, et al: Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer. Hum Cell. 22:101–106. 2009. View Article : Google Scholar : PubMed/NCBI
36	Enomoto T, Fujita M, Inoue M, et al: Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium. Cancer Res. 53:1883–1888. 1993.PubMed/NCBI
37	Wilkening S, Bermejo JL and Hemminki K: MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis. 28:2262–2267. 2007. View Article : Google Scholar : PubMed/NCBI
38	Hu Z, Jin G, Wang L, Chen F, Wang X and Shen H: MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies. Cancer Epidemiol Biomarkers Prev. 16:2717–2723. 2007. View Article : Google Scholar : PubMed/NCBI
39	Wan Y, Wu W, Yin Z, Guan P and Zhou B: MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis. BMC Cancer. 11:2082011. View Article : Google Scholar : PubMed/NCBI
40	Wo X, Han D, Sun H, et al: MDM2 SNP309 contributes to tumor susceptibility: a meta-analysis. J Genet Genomics. 38:341–350. 2011.
41	Li Y, Zhao H, Sun L, Huang L, Yang Q and Kong B: MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis. Hum Cell. 24:57–64. 2011. View Article : Google Scholar : PubMed/NCBI
42	Arva NC, Gopen TR, Talbott KE, et al: A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem. 280:26776–26787. 2005. View Article : Google Scholar : PubMed/NCBI